ALLK - Allakos Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

Allakos Inc.

975 Island Drive
Suite 201
Redwood City, CA 94065
United States

Full Time Employees77

Key Executives

NameTitlePayExercisedYear Born
Dr. Robert AlexanderCEO & Director761.07kN/A1970
Dr. Adam L. TomasiPres, COO & Sec.571.07kN/A1970
Dr. Henrik Sandvad RasmussenChief Medical Officer424.54kN/A1959
Mr. Leo J. RedmondCFO & Principal Accounting OfficerN/AN/AN/A
Dr. Ruby Casareno Ph.D.VP of Technical OperationsN/AN/AN/A
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Allakos Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutic antibodies targeting allergic, inflammatory, and proliferative diseases. The company is developing AK002 for the treatment of eosinophilic gastritis and eosinophilic gastroenteritis, urticaria, indolent systemic mastocytosis, and severe allergic conjunctivitis. Allakos Inc. was founded in 2012 and is headquartered in Redwood City, California.

Corporate Governance

Allakos Inc.’s ISS Governance QualityScore as of October 4, 2019 is 10. The pillar scores are Audit: 2; Board: 8; Shareholder Rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.